A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Parsaclisib (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms CITADEL-204
- Sponsors Incyte Corporation
- 17 Jul 2024 Status changed from active, no longer recruiting to completed.
- 01 Feb 2024 Planned End Date changed from 29 Dec 2023 to 31 May 2024.
- 01 Feb 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.